Molecular basis of hypertension, dyslipidemia and insulin resistance (metabolic syndrome)
Date: 30.4.2007
Aims: Elucidation of responsible genetic determinants relevant for understanding the pathogenesis of cardiovascular diseases and their more rational prevention and therapy.
Expected results: Collaboration with the American company Bethesda Pharmaceuticals, Inc. will make it possible to test drugs with potential more efficient control of metabolic as well as haemodynamic disorders typical for the metabolic syndrome. An example of such analysis is discovery of telmisartan (angiotensin II receptor antagonist, used in the Czech Republic for treatment of hypertension) as partial agonist of PPAR gamma, gene for antidiabetic effects of thiazolidinediones (Benson et al., 2004). Companies Bethesda Pharmaceutical Inc. and Danube Clone s.r.o. will contribute to the financing of the Center in this area.
Verifiable outputs: Publications and methodological know-how in the form of practically utilizable diagnostic method and analyses allowing prevention and rational therapy of cardiovascular diseases.
"www.img.cas.cz":[ http://www.img.cas.cz/cag/research.shtml#chapter2]
Related articles
New Way To Target And Kill Antibiotic-resistant Bacteria Found - Putting bacteria on birth control could stop the spread of drug-resistant microbes, and researchers at the University of North Carolina at Chapel Hill have found a way to do just that (13.7.2007)
Antibiotic resistance countered - US scientists believe they may have found a way to stop the growing problem of bacteria becoming resistant to current drug treatments (11.7.2007)
